Related references
Note: Only part of the references are listed.Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
Stefano Fogli et al.
CANCER TREATMENT REVIEWS (2020)
Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
Molika Emmeline Keeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment
Roberto Tamma et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
The tumor microenvironment in renal cell cancer
James W. Mier
CURRENT OPINION IN ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
Isabel Heidegger et al.
FRONTIERS IN ONCOLOGY (2019)
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
Charlene M. Mantia et al.
CANCER (2019)
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
David Cella et al.
LANCET ONCOLOGY (2019)
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy
Nizar Tannir et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
Rosa Maria Nadal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Ilaria Grazia Zizzari et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
Chung-Han Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
Rohan Garje et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Elise A. Chong et al.
BLOOD (2017)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
Yana G. Najjar et al.
CLINICAL CANCER RESEARCH (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer (vol 543, pg 728, 2017)
Xin Lu et al.
NATURE (2017)
Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach
Shankar Siva et al.
NATURE REVIEWS UROLOGY (2017)
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.
Marianna Nuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma
Peter J. Siska et al.
JCI INSIGHT (2017)
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
Simon Chowdhury et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Stephane Chevrier et al.
CELL (2017)
Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions
Jan T. Poleszczuk et al.
CANCER RESEARCH (2016)
miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction
Margherita Gigante et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
JAMA ONCOLOGY (2016)
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
Alessia Mennitto et al.
THERAPEUTIC ADVANCES IN UROLOGY (2016)
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
Aurelie Guislain et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2015)
International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
Ariana Znaor et al.
EUROPEAN UROLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antitumor activity of anti-PD-1 in combination with tyrosine kinase inhibitors in a preclinical renal cell carcinoma model
Gregg Masters et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
Anna R. Kwilas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Asim Amin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Phase 1 Dose-Escalation Trial of Tremelimumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
CANCER (2011)
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Eric Tartour et al.
CANCER AND METASTASIS REVIEWS (2011)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
Antonia Busse et al.
EUROPEAN JOURNAL OF CANCER (2011)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Ingrid M. E. Desar et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R. Kumar et al.
BRITISH JOURNAL OF CANCER (2009)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine
M. Gigante et al.
MOLECULAR IMMUNOLOGY (2009)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Michael L. Nickerson et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Re: Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial
Shahrokh F. Shariat et al.
EUROPEAN UROLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Interferon-alpha (IFN-α)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients
Margherita Gigante et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hernatopoiesis associated with elevated levels of VEGF
Yuhui Huang et al.
BLOOD (2007)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
R. Houston Thompson et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Role of immature myeloid cells in mechanisms of immune evasion in cancer
S Kusmartsev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
BI Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation
MM Dikov et al.
JOURNAL OF IMMUNOLOGY (2005)
Update on the role of interleukin 2 and other cytokines in the treatment of patients with Stage IV renal carcinoma
MB Atkins et al.
CLINICAL CANCER RESEARCH (2004)
The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis
RE Barry et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas
X Na et al.
JOURNAL OF UROLOGY (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Share Paper
